Brought to you by 
Novo Nordisk licenses Emisphere's eligen technology
14 Nov 2016
Executive Summary
Novo Nordisk AS licensed rights to drug delivery company Emisphere Technologies' eligen carrier technology for use in developing oral versions of its glucagon-like peptide 1 (GLP-1) receptor agonists for Type II diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo Nordisk licenses Emisphere's eligen technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice